We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Investor “conspiracy theories” are real in immuno-oncology, something Merck & Co. knows all too well. So well, in fact, that the company recently changed up its communications game to address investor fears directly.